RegulatoryCompany release

AchieveRx completes cytisinicline stability batches, keeps Q4 2026 NDA resubmission plan

🇺🇸 Achieve Life Sciences, Inc. (ACHV) · Tue 10 Nov 2026

The company, formerly Achieve Life Sciences, reported Q3 results and said it still expects possible FDA approval of its smoking cessation candidate by the end of Q2 2027.

AchieveRx, formerly Achieve Life Sciences, said on 10 November 2026 that it has completed three commercial-scale stability batches of cytisinicline at Adare, its US manufacturer. The company announced the milestone alongside its third-quarter results.

The company maintains that it will resubmit its New Drug Application (NDA) to the US Food and Drug Administration in the fourth quarter of 2026. It expects approval could come by the end of the second quarter of 2027. Cytisinicline is being developed as a smoking cessation treatment.

AchieveRx also presented 52-week data from the ORCA-OL study, reporting a quit rate of 31.2% and no new safety signals. It reported cash of $201.5 million at the end of the quarter.

The information available does not detail the content of the planned resubmission, the specific FDA feedback behind it, or how the stability data will feature in the filing.

What it means for your team

  • Completion of commercial-scale stability batches is a manufacturing and quality milestone that typically supports the CMC section of a marketing application.
  • The stated timeline puts the NDA resubmission in Q4 2026 and a potential approval decision by end of Q2 2027; teams tracking the smoking cessation market can watch for confirmation of the filing.
  • The absence of new safety signals in 52-week ORCA-OL data is relevant to pharmacovigilance planning, though the regulator's assessment will determine its weight.

Company's press release (SEC filing): Achieve Life Sciences, Inc. ↗

Article written by VigiEye from the official source (Achieve Life Sciences, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Regulatory All →